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Abstract 
Non-small-cell lung cancer (NSCLC) is a type of malignancy with progressive metastasis having poor prognosis and 
lowered survival resulting from late diagnosis. The therapeutic approaches for the treatment of this incurable cancer 
are chemo- and radiotherapy. Since current treatments are insufficient and because of drug-induced undesirable side 
effects and toxicities, alternate treatments are necessary and critical. The role of melatonin, produced in and released 
from the pineal gland, has been documented as a potential therapy for NSCLC. Melatonin prevents tumor metastasis 
via inducing apoptosis processes and restraining the autonomous cell proliferation. Moreover, melatonin inhibits 
the progression of tumors due to its oncostatic, pro-oxidant and anti-inflammatory effects. As a result, the combined 
treatment with melatonin and chemotherapy may have a synergistic effect, as with some other tumors, leading to 
a prolonged survival and improved quality of life in patients with NSCLC. This review summarizes the available data, 
based on the molecular mechanisms and related signaling pathways, to show how melatonin and its supplementa-
tion function in NSCLC.
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Introduction
Lung cancer is a leading cause of cancer-related mor-
tality and morbidity in the global population [1]. Histo-
logically, there are two types: small-cell lung cancer and 
non-small-cell lung cancer (NSCLC). Approximately, 
85% of lung cancer cases are classified as NSCLC, and the 
majority of these patients present at advanced stage at the 
time of diagnosis [1, 2]. NSCLC comprises three subtypes 
including adenocarcinoma, squamous cell carcinoma and 
large-cell carcinoma. NSCLC has poor prognosis and 
based on the International Staging System for Lung Can-
cer, is related to locally advanced or metastatic disease 
with stage IIIB and stage IV [3]. The expected median 
survival of NSCLC is 6 months and a 5-year survival of 
2% is anticipated [4]. Moreover, the symptoms of the dis-
ease such as chest pain, hoarseness, weight loss, cough-
ing and wheezing can significantly lower the functional 
independence of NSCLC patients [5, 6]. Chemotherapy 
a proven therapy for NSCLC and improves patient’s sur-
vival. However, it often has treatment-associated toxicity 
that reduces its therapeutic potential. Thus, searching for 
alternative and complementary treatments, to reduce the 
adverse effects and enhance the therapeutic properties of 
chemotherapy, is an essential issue.
As a neurohormonal agent, melatonin (N-acetyl-
5-methoxytryptamine) is a highly investigated anticancer 
agent which is endogenously synthesized and secreted 
by the pineal gland. Based on its circadian rhythm, the 
secretion of melatonin primarily occurs during night 
hours [7]. Melatonin is also produced by the other organs 
such as skin [8], gastrointestinal tract [9], lymphocytes 
[10], retina [11] and so forth [12]. Recently, some of the 
main roles of melatonin, including antioxidant, anxio-
lytic, antihypertensive and sedative effects have been 
demonstrated [13]. Also, a dose-dependent analgesic 
property of melatonin has been reported in experimen-
tal studies [14, 15]. The free radical scavenging capabil-
ity of melatonin makes it an antioxidant agent in normal 
cells melatonin also has anti-inflammatory properties 
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[16], while in cancer cells it has pro-oxidant activity [17, 
18] and is involved in immune responses [19]. Numer-
ous studies have reported positive effects of melatonin 
in the therapy of cancer. Previous non-clinical trials have 
shown that melatonin inhibits cell proliferation of tumor 
cells [7, 20, 21] and many clinical trials have documented 
that melatonin has beneficial effects on the survival in 
patients with cancer [22–24]. Additionally, melatonin 
has clinical benefits in gastric cancer [25], non-small-cell 
lung cancer [26], head and neck cancer [27] and the other 
cancers [28]. To evaluate the role of melatonin in NSCLC, 
based on the published data, the present review assesses 
the current knowledge of melatonin effectiveness as a 
potential treatment for NSCLC. In this review, we dis-
cuss multiple anticancer properties of melatonin, includ-
ing anti-metastatic, tumor growth inhibition, apoptosis 
induction, anti-inflammatory, anti-proliferative, antioxi-
dant, and its role in reducing the chemo-radiotherapy 
side-effects and increasing patient’s survival.
Melatonin, a metastasis inhibitor in NSCLC
The migration of tumor cells, known as metastasis, is a 
process that worsens the stage of cancer due to its inva-
sion of the surrounding tissues and other organs. Metas-
tasis lowers the disease prognosis as well as patient’s 
the survival time [29]. Melatonin is capable of restrain-
ing the proliferation of tumor cells and inhibits their 
autonomous growth. Additionally, melatonin selectively 
blocks the signal transduction of pathways of tumor cells 
and especially those involved in metastasis [30–32]. By 
regulating the structure formation of microtubule and 
microfilament, melatonin inhibits metastasis and inva-
sive properties of tumors [33]. Also, melatonin typically 
prolongs the cell cycle and delays tumor cell mitosis and 
inhibits cancer cells from entering the S phase [34, 35]. 
Specifically, melatonin has been shown to inhibit prolifer-
ation of NSCLC cells, which are responsible for metasta-
sis in advanced lung cancer [36]. In summary, melatonin 
prevents the progression of tumor cells and metastatic 
processes by interacting with intracellular mechanisms 
related to proliferation and the invasion (Fig. 1).
Melatonin exerts its anti‑metastatic roles 
through inhibiting the c‑Jun N‑terminal kinase (JNK)/
mitogen activated protein kinase (MAPK) signaling 
pathway
Down-regulation of occludin, as a trans-membrane pro-
tein related to tight junctions (TJ), is associated with 
invasiveness, staging and the high potential of metasta-
sis in epithelial cancers [37, 38]. TJ paracellular trans-
portis modulated via MAPK signaling pathway through 
down- and up-regulation of the expression of the several 
TJ proteins [39]. JNK is activated in numerous tumor 
cells and may have some transforming activities in sev-
eral oncogenes [40]. The dysfunction and expression 
of occludin proteins are correlated with metastasis and 
tumor development [41, 42]. Zhou et al. [36] showed that 
treatment with melatonin markedly increased the expres-
sion of occludin in A549 cells. This overexpression on 
the cell surface enhanced the tight connection between 
cells to restrain A549 cell metastasis. In addition, mela-
tonin inhibited the JNK/MAPK pathway based on its 
anti-migration effect. Clearly, the inhibitory properties of 
melatonin in lung adenocarcinoma should be more care-
fully evaluated.
Melatonin inhibits tumor growth by regulation 
of epidermal growth factor receptor (EGFR) in NSCLC
Epidermal growth factor receptor is a tyrosine kinase 
receptor overexpressed on the surface of NSCLC tumor 
cells [43]. It plays major functions in tumor cell survival 
and activated phosphorylation of EGFR leads to the 
phosphorylation of downstream proteins that contribute 
to metastasis, invasion, cell proliferation and inhibition 
of apoptosis [44]. The intracellular mutation of EGFR or 
its overexpression in NSCLC patients has been observed 
in 43–89% of cases [45]. Consequently, the signaling 
pathway related to EGFR is inhibited by blocking the 
receptor using anti-EGFR antibodies or small molecules 
restraining the EGFR tyrosine kinase [46]. Notably, the 
inhibitors of EGFR tyrosine kinase, for instance erlotinib 
and gefitinib, are a standard therapy to treat patients with 
Fig. 1 Schematic representation in targeting different signaling 
pathways using melatonin and its metabolites as a novel therapeutic 
strategy in the treatment of lung cancer
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advanced NSCLC [47, 48]. The inactivating effect of mel-
atonin on the growth of circadian-dependent tumor cells 
is mediated by EGFR suppression [49, 50]. As mentioned 
earlier, melatonin participates in EGFR signaling pathway 
regulation and this inhibitory activity could be in focus to 
discover more effective drugs.
Melatonin induces its apoptotic properties 
through regulating B cell lymphoma 2 (Bcl‑2)/Bax balance
Bcl-2, known as a proto-oncogene, was initially discov-
ered in a follicular B-cl and currently has been confirmed 
in numerous tumors. The Bcl-2 protein is situated in the 
mitochondrial inner membrane and suppresses intrinsic 
apoptosis through arresting the cell in the G0/G1 phase 
of the cell cycle to prolong the survival of the tumor cell 
[51, 52]. The biological roles of Bcl-2 protein correlate 
with the protection of cancer cells from apoptosis and 
medication-induced death [53]. This protein has been 
assessed in various cancers to clear the predictive and 
prognostic significances, including NSCLC [54].
Similarly, Bax is a member of Bcl-2 family also located 
in mitochondria; it changes the permeability of its mem-
brane to trigger caspases activation, leading to apoptosis 
[55, 56]. Bax proteins are expressed in all tumor cells, but 
their function is inactivated by Bcl-2 proteins [57, 58]. 
Melatonin induces the apoptosis in various tumors by 
regulating the apoptotic signaling pathway of Bcl-2 [59, 
60]. For example, melatonin down-regulates the expres-
sion of Bcl-2 and up-regulates Bax expression leading to 
apoptosis in lung adenocarcinoma cells [61]. Pretreat-
ment with melatonin enhances the berberine-mediated 
up-regulation of Bax proteins and down-regulation of 
Bcl-2 in lung cancer cells [62]. Also, melatonin decreases 
the phosphorylation of Bcl-2 in H1975 NSCLC result-
ing in apoptosis [63]. To whether melatonin and chemo-
therapy co-treatment is more effective in increasing the 
NSCLC patient survival via this apoptotic induction, 
clinical trials should be performed. In the identified 
in  vitro study, pretreatment with melatonin effectively 
increased the berberine-induced downregulation of Bcl-2 
and upregulation of the cleaved caspase-9, caspase-3, 
Bax and PARP as compared with treatment by berberine 
alone. This pretreatment also enhanced the cytochrome 
C release from a human lung cell line H1299 [62] (Fig. 2).
Melatonin and its anti‑inflammatory actions in relation 
to lung cancer
The cyclooxygenase 2 (COX-2) signaling is implicated in 
migration, growth and angiogenesis of lung cancer cells 
[64]. Its overexpression appears in different human can-
cers including cancer of the lung. The expression of COX-2 
and the sequential production of prostaglandin E2 are 
capable of up-regulating phosphoinositide-3-kinase (PI3K), 
EGFR and ERK1/2 signaling to trigger cell proliferation, 
angiogenesis, metastasis and invasion of tumor cells [65]. 
Melatonin has anti-inflammatory and antitumor proper-
ties through inhibiting the expression of COX-2 [66]. The 
expression of COX-2 is controlled by the binding of sev-
eral co-activators and transactivators to the corresponding 
sites on its promoter. Among all known regulatory agents 
distributing in the region of COX-2 transcription start site 
core promoter, the binding site of NF-κB is essential for 
the promoter activity of COX-2 [67, 68]. Melatonin may 
enhance the inhibition of COX-2 expression with this effect 
being mediated by stimulation of p50 nuclear factor (NF)-
κB translocation from cell nuclei to cytosol [62].
The Raf/MEK/ERK and PI3K/Akt signaling also play 
critical roles in the growth of tumor cells and are impli-
cated in the cancer-associated gene expression of COX-2 
and human telomerase reverses transcriptase (hTERT). 
Pretreatment with melatonin (1.0  mM), in an in  vitro 
investigation, significantly promoted the berberine-
induced inhibition of Akt and ERK1/2 protein phos-
phorylation [62]. Therefore, Akt/ERK signaling should 
be considered as an important target for melatonin in 
increasing the inhibition of berberine-mediated growth 
in NSCLC cells and further studies are required. Caspase 
cascade activation is identified as an important basis of 
the apoptosis pathway. The release of cytochrome C from 
mitochondria into the cytosol is known as the precondi-
tion for caspase-dependent apoptosis.
Fig. 2 Proposed oncostatic actions of melatonin its metabolites on 
suppressing NSCLC cells metastasis
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Melatonin inhibits the proliferation of tumor cells 
through suppressing activating enhancer‑binding 
protein‑2β (AP‑2β)/hTERT signaling pathway
HTERT known as lung tumorigenesis hallmark, is highly 
expressed in the cancer cells of the lung; it is strictly reg-
ulated by AP-2β [69]. HTERT is a critical component of 
human telomerase which lengthens the ends of linear 
chromosome as well as maintaining their stability; this 
results in cellular immortalization [70]. HERT is over-
expressed in variety cancers including lung cancer [71]. 
AP-2β displays its biological effects via the tumor-related 
gene hTERT activation. AP-2β is involved in different 
cell processes such as cell growth, apoptosis and the dif-
ferentiation of tissue during embryogenesis. Melatonin 
reportedly downregulates AP-2β and hTERT expres-
sion, thereby suppressing cell proliferation [62]. Thus, the 
oncostatic action of melatonin includes inhibition of the 
progression of lung tumors via suppression the AP-2β/
hTERT signaling pathway.
Immunomodulatory role of melatonin in NSCLC
Melatonin also stimulates monocyte/macrophage, lym-
phocyte and natural killer cells to increase immunosur-
veillance. Moreover, lymphoid cells synthesize melatonin, 
this additional source of melatonin helps to regulate the 
human immune system by acting in an autocrine and 
paracrine manner [72]. Immunoenhancing ability of 
melatonin, with the enhancement of the production of 
pro-inflammatory cytokines including interleukin 1 (IL-
1), IL-6, IL-12 and tumor necrosis factor-α (TNF-α) has 
been shown [73]. Furthermore, T-helper cells have a key 
role in protecting against malignancy, and melatonin also 
enhances the response of this cell by releasing IL-2, IL-10 
and interferon gamma (IFN-γ) [74, 75]. Moreover, mela-
tonin controls inflammation by inhibiting NF-kB. This 
leads to a reduced overproduction of leukocytes and pro-
inflammatory cytokines [76]. Melatonin limits radiation-
induced inflammation in the lung by decreasing oxidative 
stress and cytokines production [77].
Melatonin, an oxidative stress regulator
In both in vivo and in vitro studies, melatonin protected 
healthy cells from treatment-related toxicity via its well 
documented antioxidant actions [78]. Toxicity, as a direct 
consequence of high levels of reactive oxygen species 
(ROS) [79, 80], causes oxidative damage to tumor and 
healthy cells, leading to unwanted side-effects. Melatonin 
is a powerful endogenous antioxidant in normal cells due 
to its ability to scavenge ROS, decrease the formation of 
free radicals, and activate antioxidant enzymes including 
glutathione peroxidase and superoxide dismutase [81, 
82]. In cancer cells, melatonin might exert pro-oxidant 
effects [18]. Therefore, melatonin may inhibit cancer 
development [83]. The effect of melatonin in increasing 
the induction of oxidative stress in tumor cells, leading to 
induce cell death in lung adenocarcinoma, was shown by 
Fan et el. [61]. Enhancing the induction of oxidative stress 
in cancer may be an important oncostatic action of mela-
tonin in NSCLC. Melatonin protects healthy cells against 
radiochemotherapy by reducing the overproduction of 
ROS [84]. For NSCLC cells, melatonin does not protect 
them from UV-induced apoptosis [85]. These combined 
abilities of melatonin should be used as a justification of 
this multifunctional agent a supplemental treatment for 
NSCLC.
Melatonin declines the side‑effects of chemotherapy 
and radiotherapy and increases survival
It has been shown that serum levels of melatonin and 
its metabolites, in comparison with those in healthy 
subjects, are lower in NSCLC patients [86, 87] and the 
concentrations further decreased due to standard chem-
otherapy [87]. Several studies have reported that mela-
tonin reduces the chemotherapy-related side effects in 
patients and animals [23, 88]. Melatonin protects blood 
cells from radiation-induced and chemotherapy-related 
damages [74, 89]. Also, it lowers the frequency of chem-
otherapy-associated stomatitis, cardiotoxicity, asthenia 
and neurotoxicity [22]. Based on data from a meta-anal-
ysis of 21 randomised controlled trials (RCTs) conducted 
in patients with solid tumors, melatonin improves the 
frequency of partial and complete responses while reduc-
ing thrombocytopenia, leucopenia, nausea, hypotension 
and vomiting [90]. In addition to reduction of adverse 
events, adding melatonin to routine medical treatment 
may improve the survival in patients with NSCLC. Lis-
soni et  al. [91] showed that melatonin in combination 
with cisplatin and etoposide significantly increased the 
survival time of NSCLC patients in a poor clinical state 
compared with chemotherapy alone. Also, chemotherapy 
was better tolerated in melatonin treatment individuals.
Conclusions
Based on the published reports, melatonin is an appro-
priate complementary treatment that should be consid-
ered to enhance the clinical benefits in NSCLC therapy 
and to improve poor outcomes. Melatonin acts by affect-
ing the related gene expression, apoptotic pathways and 
the proliferation of tumor cells (Fig. 3). In summary, sev-
eral clinical trials have been designed to assess the poten-
tial beneficial effects of melatonin supplementation in 
the treatment of lung cancer and NSCLC, in particular. 
Additional RCTs should be carried out to determine the 
effectiveness of melatonin as a co-treatment for NSCLC.
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